[Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].

Abstract

Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. Nevertheless, it causes haemorheological changes, which in turn may affect smaller blood vessel circulation. Our study was conducted on a pool of chronic uraemic patients under hemodialytic treatment who were given erythropoietin therapy. Substantial increases in overall blood viscosity and red cell aggregation were recorded, with no change in erythrocyte deformation. An increase in cardiovascular morbidity might occur in these patients who are already liable to this condition. Several years will have to elapse and thorough studies will have to be conducted on a large number of patients, to have conclusive evidence on this point.

• Authors: M Melappioni, R Giansanti, M Boemi, M Baldassari, S Baldini, T Pierangeli, R Radicioni, P Fumelli, N Panichi
• Journal: Minerva urologica e nefrologica = The Italian journal of urology and nephrology (Minerva Urol Nefrol) 1992 Apr-Jun Vol. 44 Issue 2 Pg. 155-9 ISSN: 0393-2249 [Print] Italy
• Vernacular Title: Alterazioni emoreologiche in seguito a trattamento con eritropoietina umana ricombinante in pazienti emodializzati cronici.
• PMID: 1411865 (Publication Type: English Abstract, Journal Article)

Chemical References

• Hemoglobins
• Immunologic Factors
• Lipids
• Recombinant Proteins
• Erythropoietin
• Fibrinogen

Topics

• Adult
• Aged
• Anemia (etiology, therapy)
• Blood Viscosity (drug effects)
• Erythrocyte Aggregation (drug effects)
• Erythrocyte Deformability (drug effects)
• Erythropoietin (adverse effects, therapeutic use)
• Female
• Fibrinogen (analysis)
• Hematocrit
• Hemoglobins (analysis)
• Humans
• Immunologic Factors (adverse effects, therapeutic use)
• Lipids (blood)
• Male
• Middle Aged
• Recombinant Proteins (adverse effects, therapeutic use)
• Renal Dialysis
• Uremia (blood, complications, therapy)